Pharmaron Joins NCI’s Chemical Biology Consortium to Fight Against Cancer
Irvine, California, June 14, 2016 – Pharmaron, a fully integrated contract research organization (CRO) offering laboratory and manufacturing services for pharmaceutical and biotech research and development, has joined a national network of scientists on the leading edge of drug discovery and development in the fight against cancer, centered at the Frederick National Laboratory for Cancer Research.
The Frederick National Lab, sponsored by the National Cancer Institute, is managing the expansion of the Chemical Biology Consortium to 22 sites around the country with world-class expertise in high-throughput screening, structural biology, medicinal chemistry, compound profiling, cancer cell biology, and animal models for oncology. Pharmaron will participate in the consortium via a research subcontract from Leidos Biomedical Research, Inc., prime contractor for the national lab.
The Chemical Biology Consortium is the discovery engine for the NCI Experimental Therapeutics (NExT) Program. The CBC is a consortium designed to facilitate the discovery and development of novel agents for the treatment of cancer by integrating chemical biology, molecular oncology research and development capabilities and resources from the government, academia and industry. Pharmaron will participate in the CBC as a Specialized Center, providing DMPK and other bio-analysis services.
As a CBC participant, Pharmaron is honored to provide R&D services to support the discovery and development of promising new molecular entities focusing on unmet medical needs in therapeutics not adequately addressed today.
The DMPK and bioanalysis platform is a comprehensive and integrated component of the drug R&D services at Pharmaron. It spans from discovery in vitro ADME, in vivo PK and PK/PD correlation, to regulatory compliant DMPK and bioanalysis, including metabolism studies using radioactive compounds. This platform has played a critical role in successfully advancing agents from early discovery to preclinical and clinical development phases for Pharmaron’s partners and collaborators. Pharmaron is confident that by working together closely with other members of the CBC, innovations from the CBC can be translated into novel and effective anti-cancer medicines.
About Pharmaron
Pharmaron is a private, premier R&D service provider for the life science industry. Founded in 2004, Pharmaron has invested in its people and facilities, and established a broad spectrum of drug R&D service capabilities, ranging from synthetic and medicinal chemistry, biology, DMPK, pharmacology and safety assessment to chemical & pharmaceutical development. With over 3,500 employees and operations in China, the U.S. and the UK, Pharmaron has an excellent track record in the delivery of R&D solutions to its partners in North America, Europe, Japan and China. For more information, please visit www.www.pharmaron.com.
About the Frederick National Laboratory for Cancer Research
The Frederick National Laboratory for Cancer Research is a federal national laboratory sponsored by the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH). The Frederick National Lab collaborates with academic, commercial, nonprofit, and government researchers to address urgent problems in biomedical research consistent with NCI’s mission. The national lab is government-owned, contractor-operated facility with Leidos Biomedical Research Inc., as its prime contractor.
康龙化成加入美国国家癌症研究所化学生物科研联盟，共同抗击癌症!
美国加州尔湾，2016年6月14日 – 康龙化成（一体化药物研发服务公司）宣布已加入以弗雷德里克国家癌症研究实验室为中心的美国国家化学生物科研联盟，作为联盟成员之一，将积极参与该组织的创新药研发，共同抗击癌症。
弗雷德里克国家实验室由美国国家癌症研究所赞助，旗下的化学生物联盟成员已扩展至22名，其高通量筛选、结构生物学、药物化学、药物综合性分析、肿瘤细胞生物学和动物模型研发平台拥有世界一流的专业技术。 康龙化成作为22名化学生物联盟成员之一，通过与Leidos Biomedical Research, Inc. 的合作（注：Leidos Biomedical Research, Inc为美国国家癌症研究实验室的总合作伙伴），将积极参与该组织活动。
作为国家癌症研究所在探索性治疗方法领域的研发引擎，化学生物联盟（CBC）旨在通过对政府、学术界、工业界化学生物学、分子肿瘤学各类研发能力的整合，促进新颖癌症治疗药物的研发。康龙化成将作为CBC联盟的专业中心之一，专门负责药物代谢及生物分析研发服务。
康龙化成有幸成为CBC联盟成员，将提供研发服务，支持前景创新药物的研发与开发，瞄准未满足需求的医疗领域。
药物代谢与生物分析平台作为康龙化成综合性一体化研发平台的核心单元之一，贯穿体外ADME,体内药代动力学和PK/PD相关性研究，符合法规的DMPK和生物分析，包括放射性化合物的代谢研究。该平台为客户的候选药物开发发挥了关键作用，贯穿药物早期发现至临床前和临床全流程。相信通过与CBC各成员的紧密合作及积极创新，将催生更多新颖的、有效的抗癌药物。
关于康龙化成
康龙化成新药技术有限公司（非上市企业），成立于2003年，是国际领先的生命科学研发服务企业。公司宗旨为“以最高水平的研发服务，帮助伙伴们成功开发新药，降低新药研发成本，提高新药研发效率”，经过多年发展，打造了全方位的临床前药物研发一体化平台，贯穿合成化学与药物化学、生物、药物代谢及药代动力学、药理、药物安全评价、工艺研发、GMP生产及制剂研发服务等各个领域。在中国、美国、英国均有运营实体，拥有员工3500多人，一流的人才队伍，高质量的研发服务，获得业界广泛认可，与北美、欧洲、日本和中国的各医药公司/机构保持长期、稳固的合作关系。详情请访问公司网站：www.www.pharmaron.com
关于弗雷德里克国家癌症研究实验室
弗雷德里克国家癌症研究实验室，由美国国家癌症研究所提供赞助的联邦国家实验室，隶属于美国国立卫生研究院（NIH）。秉承NIH使命，为解决生物医学界的紧迫问题，弗雷德里克国家癌症研究实验室与学术界、商业界、非盈利组织及政府机构科研人员开展广泛合作。该国立实验室由Leidos Biomedical Research Inc. 作为总合作伙伴，开展各类合作与研发活动。